Leishmaniasis: Drug Therapy

Therapy goals

  • Elimination of the pathogens
  • Avoidance of complications

Therapy recommendations

  • In visceral leishmaniasis, it is important to determine whether organ complications (especially spleen, liver) have already occurred before starting therapy.
    • Liposomal amphotericin B (antifungal agent; first-line agent).
    • Miltefosine (alkyphosphocholine) (second-line agent).
    • Antimony preparation (pentavalent antimony) (reserve drug).
  • Cutaneous leishmaniasis does not require treatment in every case. Often it heals spontaneously (by itself) after six months to a year.
    • If necessary, treatment with: Antimony preparation (pentavalent antimony; first-line agent), (Liposomal) Amphotericin B.
      • For cutaneous single foci caused by Old-World Cutaneous Leishmaniasis (OWCL; L. tropica major, L. tropica minor, L. donovani, L. donovani infantum, L. archibaldi): local infiltration of antimony.
      • In infections caused by pathogens of the New World (NWCL; English New World China Land; L. brasiliensis, L. mexican – mexicana, L. mexicana – pifanoi): systemic administration of antimony.
  • Mucocutaneous leishmansiosis must be treated systemically (affecting the entire body) to prevent subsequent mucosal infestation.
    • Treatment with: Antimony preparation (pentavalent antimony; first-line agent), (liposomal) amphotericin B /second-line agent.